The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis
Open accessAbstract
BACKGROUND: A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown. METHODS: Applying the mendelian randomisation principle, we used single nucleotide polymorphisms (SNPs) in the gene IL6R to evaluate the likely efficacy and safety of IL6R inhibition for primary prevention of coronary heart disease. We compared genetic findings with the effects of tocilizumab reported in randomised trials in patients with rheumatoid arthritis. FINDINGS: In 40 studies including up to 133,449 individuals, an IL6R SNP (rs7529229) marking a non-synonymous IL6R variant (rs8192284; p.Asp358Ala) was associated with increased circulating log interleukin-6 concentration (increase per allele 9·45%, 95% CI 8·34-10·57) as well as reduced C-reactive protein (decrease per allele 8·35%, 95% CI 7·31-9·38) and fibrinogen concentrations (decrease per allele 0·85%, 95% CI 0·60-1·10). This pattern of effects was consistent with IL6R blockade from infusions of tocilizumab (4-8 mg/kg every 4 weeks) in patients with rheumatoid arthritis studied in randomised trials. In 25,458 coronary heart disease cases and 100,740 controls, the IL6R rs7529229 SNP was associated with a decreased odds of coronary heart disease events (per allele odds ratio 0·95, 95% CI 0·93-0·97, p=1·53×10(-5)). INTERPRETATION: On the basis of genetic evidence in human beings, IL6R signalling seems to have a causal role in development of coronary heart disease. IL6R blockade could provide a novel therapeutic approach to prevention of coronary heart disease that warrants testing in suitably powered randomised trials. Genetic studies in populations could be used more widely to help to validate and prioritise novel drug targets or to repurpose existing agents and targets for new therapeutic uses. FUNDING: UK Medical Research Council; British Heart Foundation; Rosetrees Trust; US National Heart, Lung, and Blood Institute; Du Pont Pharma; Chest, Heart and Stroke Scotland; Wellcome Trust; Coronary Thrombosis Trust; Northwick Park Institute for Medical Research; UCLH/UCL Comprehensive Medical Research Centre; US National Institute on Aging; Academy of Finland; Netherlands Organisation for Health Research and Development; SANCO; Dutch Ministry of Public Health, Welfare and Sports; World Cancer Research Fund; Agentschap NL; European Commission; Swedish Heart-Lung Foundation; Swedish Research Council; Strategic Cardiovascular Programme of the Karolinska Institutet; Stockholm County Council; US National Institute of Neurological Disorders and Stroke; MedStar Health Research Institute; GlaxoSmithKline; Dutch Kidney Foundation; US National Institutes of Health; Netherlands Interuniversity Cardiology Institute of the Netherlands; Diabetes UK; European Union Seventh Framework Programme; National Institute for Healthy Ageing; Cancer Research UK; MacArthur Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“genetic evidence suggests that IL-6 may be causal for atherosclerotic cardiovascular disease, 24,25”
From Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide (2026) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genome-wide association studies (GWAS), meta-analysis, exome analysis and single nucleotide polymorphism (SNP) mapping have associated IL-6, IL-6R and gp130 with inflammatory diseases such as RA and coronary artery disease (263–269).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [265]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We also identified associations between IL6R pQTLs and CAD, rheumatoid arthritis and 7 other disease traits (Supplementary Table S12), thereby supporting the findings of the study69.”
From Genetic determinants of plasma protein levels in the Estonian population (2024) · cites this paper as [69]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“One large study reported a near significant effect ( P = 0.06) of a functional variant causing impaired signalling at the IL-6 receptor with reduced risk of developing diabetes mellitus 44.”
From Type 2 diabetes mellitus and psychological stress — a modifiable risk factor (2017) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“A previous study has shown a link between IL6R and CAD69.”
From Genetic determinants of plasma protein levels in the Estonian population (2024) · cites this paper as [69]
In the citing paper
“Confirming the role of IL-6 in health, in a large Mendelian randomization analysis, the IL6R SNP rs7529229, marking a non-synonymous IL6R variant (rs8192284; p.Asp358Ala), was associated with increased circulating IL-6 levels24.”
From Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty (2018) · cites this paper as [24]
In the citing paper
“Variants in the IL6R gene have been found to be associated with increased risk of coronary artery disease24, rheumatoid arthritis, atrial fibrillation, and abdominal aortic aneurysm, and with increased susceptibility to asthma, type 1 diabetes, and depression36,37.”
From Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty (2018) · cites this paper as [24]
In the citing paper
“CETP inhibitors exert their relatively modest cardioprotective effects on the basis that in addition to their HDL-C raising effects, more potent CETP inhibitors also lower apolipoprotein B 22,23,75 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [23]
In the citing paper
“The approach outlined here to obtaining a scaling estimate has generally held true for lipid-lowering therapies and risk of cardiovascular disease 22,23,40,92 but there are several potential reasons why the derivation of such a scaling for other therapeutic target-indication pairs may pose a challenge.”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [23]
In the citing paper
“However, using SNPs located in CETP associated with HDL-C at genome-wide significant levels in a drug-target MR suggests that modifying HDL-C via CETP, is likely to reduce risk of CHD 23,103 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [23]
In the citing paper
“CETP 23 variants associate with of CHD; APOA1 117 variants do not associate with risk of CHD”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [23]
In the citing paper
“Various statistical methods have been proposed to reduce weak instrument bias due to sample overlap and bias due to winner’s curse (see Section 3) 43– 45 .”
From Guidelines for performing Mendelian randomization investigations (2020) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,762
Haploview: analysis and visualization of LD and haplotype maps
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth457 · Cited by 14,563
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Cited by
Sorted by citations
Items 401–500 of 999
Myasoedova, E., Davis, J. M., Roger, V. L., Achenbach, S. J., & Crowson, C. S. (2021) · The Journal of Rheumatology · doi:10.3899/jrheum.200842 · Cited by 42
Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis
Mathieu, S., Couderc, M., Pereira, B., Tournadre, A., Dubost, J., Soubrier, M., & Glace, B. (2013) · Biologics · doi:10.2147/btt.s52003 · Cited by 44
Liu, Y., Li, B., Ma, Y., Huang, Y., Ouyang, F., & Liu, Q. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.745757 · Cited by 42
Roy, P. K., Islam, J., & Lalhlenmawia, H. (2023) · The Egyptian Heart Journal · doi:10.1186/s43044-023-00352-7 · Cited by 51
Schmidt, A. F., Bourfiss, M., Alasiri, A., Anton, E. P., Chopade, S., van Vugt, M., van der Laan, S. W., Groß, C., Clarkson, C., Henry, A., et al. (2023) · Science Advances · doi:10.1126/sciadv.add4984 · Cited by 43
Circulating “LncPPARδ” From Monocytes as a Novel Biomarker for Coronary Artery Diseases
Cai, Y., Yang, Y., Chen, X., He, D., Zhang, X., Wen, X., Hu, J., Fu, C., Qiu, D., José, P. A., et al. (2016) · Medicine · doi:10.1097/md.0000000000002360 · Cited by 42
Inferring Causal Relationships between Risk Factors and Outcomes Using Genetic Variation
Burgess, S., Foley, C. N., & Zuber, V. (2019) · Wiley eBooks · doi:10.1002/9781119487845.ch23 · Cited by 40
Human Genomics and Drug DevelopmentPreprint
Schmidt, A. F., Hingorani, A. D., & Finan, C. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a039230 · Cited by 40
Yuan, S., Merino, J., & Larsson, S. C. (2023) · Diabetologia · doi:10.1007/s00125-023-05879-7 · Cited by 42
Smith, M. L., Bull, C. J., Holmes, M. V., Smith, G. D., Sanderson, E. C. M., Anderson, E. L., & Bell, J. A. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104503 · Cited by 40
Ferreira, J. P., Vasques‐Nóvoa, F., Neves, J. S., Zannad, F. M., & Leite-Moreira, A. F. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117461 · Cited by 41
Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled
Elewa, U., Sánchez-Niño, M. D., Martín-Cleary, C., Fernández‐Fernández, B., Egido, J., & Ortíz, A. (2012) · International Urology and Nephrology · doi:10.1007/s11255-012-0271-4 · Cited by 43
RVX 208: A novel BET protein inhibitor, role as an inducer of apo A‐I/ HDL and beyond
Ghosh, G. C., Bhadra, R., Ghosh, R. K., Banerjee, K., & Gupta, A. (2017) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12265 · Cited by 42
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Storey, B. C., Staplin, N., Haynes, R., Reith, C. A., Emberson, J., Herrington, W. G., Wheeler, D. C., Walker, R. J., Fellström, B., Wanner, C., et al. (2017) · Kidney International · doi:10.1016/j.kint.2017.09.011 · Cited by 43
Activating mutations of the gp130/JAK/STAT pathway in human diseases
Lokau, J., & Garbers, C. (2018) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2018.11.007 · Cited by 41
Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives
Patoulias, D., Stavropoulos, K., Imprialos, K. P., Athyros, V. G., Grassos, H., Doumas, M. N., & Faselis, C. J. (2020) · Current Vascular Pharmacology · doi:10.2174/1570161118666200318104434 · Cited by 41
Almeida‐de‐Souza, J., Santos, R., Lopes, L., Abreu, S., Moreira, C. M. M., Padrão, P., Mota, J. A. P. S., & Moreira, P. A. M. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1479-y · Cited by 40
Why START ? Reflections that led to the conduct of this large long‐term strategic HIV trial
The INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group (2015) · HIV Medicine · doi:10.1111/hiv.12227 · Cited by 39
Miceli, G., Basso, M. G., Rizzo, G., Pintus, C., & Tuttolomondo, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314914 · Cited by 42
Giollabhui, N. M., Slaney, C., Hemani, G., Foley, É. M., van der Most, P. J., Nolte, I. M., Snieder, H., Smith, G. D., Khandaker, G. M., & Hartman, C. A. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03372-w · Cited by 51
Robert, J., Lehner, M., Frank, S., Perisa, D., von Eckardstein, A., & Rohrer, L. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.301363 · Cited by 39
Tay, J., Goss, A. M., Locher, J. L., Ard, J. D., & Gower, B. A. (2019) · The journal of nutrition health & aging · doi:10.1007/s12603-019-1260-4 · Cited by 39
Robinson, T., Martin, R. M., & Yarmolinsky, J. (2020) · International Journal of Cancer · doi:10.1002/ijc.32947 · Cited by 40
Premature Atherosclerotic Cardiovascular Disease: What Have We Learned Recently?
Mahtta, D., Khalid, U., Misra, A., Samad, Z. Z., Nasir, K., & Virani, S. S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00862-8 · Cited by 39
Slaney, C., Sallis, H., Jones, H. J., Dardani, C., CHARGE Inflammation Working Group, Tilling, K. M., Munafo, M. R., Smith, G. D., Mahedy, L., & Khandaker, G. M. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.02.010 · Cited by 39
Ning, Z., Huang, Y., Lu, H., Zhou, Y., Tu, T., Ouyang, F., Liu, Y., & Liu, Q. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07467-8 · Cited by 36
IL-6 Signaling in Immunopathology: From Basic Biology to Selective Therapeutic Intervention
Schumertl, T., Lokau, J., & Garbers, C. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s485684 · Cited by 45
Interleukin-6 “Trans-Signaling” and Ischemic Vascular Disease: The Important Role of Soluble gp130
Morieri, M. L., Passaro, A., & Zuliani, G. (2017) · Mediators of Inflammation · doi:10.1155/2017/1396398 · Cited by 40
Increased Cardiovascular Risk in Patients with Adrenal Insufficiency: A Short Review
Rahvar, A., Haas, C. S., Danneberg, S., & Harbeck, B. (2017) · BioMed Research International · doi:10.1155/2017/3691913 · Cited by 40
Bargieł, W., Cierpiszewska, K., Maruszczak, K., Pakuła, A., Szwankowska, D., Wrzesińska, A., Gutowski, Ł., & Formanowicz, D. (2021) · Medicina · doi:10.3390/medicina57070701 · Cited by 41
Consumption of ultra-processed foods and IL-6 in two cohorts from high- and middle-income countries
dos Santos, F. S., Mintem, G. C., de Oliveira, I. O., Horta, B. L., Ramos, E., Lopes, C., & Gigante, D. P. (2022) · British Journal Of Nutrition · doi:10.1017/s0007114522000551 · Cited by 41
Circulating levels of cytokines and risk of cardiovascular disease: a Mendelian randomization study
Wei, T., Zhu, Z., Liu, L., Liu, B., Wu, M., Zhang, W., Cui, Q., Liu, F., & Zhang, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1175421 · Cited by 39
The Role of C-reactive Protein in Patient Risk Stratification and Treatment
Arroyo‐Espliguero, R., Viana-Llamas, M. C., Silva, J. A., & y, P. A. (2021) · European Cardiology Review · doi:10.15420/ecr.2020.49 · Cited by 41
Miwa, K., Tanaka, M. R., Okazaki, S., Furukado, S., Sakaguchi, M., Mochizuki, H., & Kitagawa, K. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300350 · Cited by 35
Zhang, H., Jia, K., Da Yu, S. U. N., & Yang, M. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26575 · Cited by 39
Atherothrombosis and the NLRP3 inflammasome – endogenous mechanisms of inhibition
Satish, M., & Agrawal, D. K. (2019) · Translational research · doi:10.1016/j.trsl.2019.08.003 · Cited by 39
Carotid intimal medial thickness in rotating night shift is related to IL1β/IL6 axis
Rizza, S., Longo, S., Piciucchi, G., Romanello, D., Mavilio, M., Montagna, M., Coppeta, L., Martelli, E., Magrini, A., & Federici, M. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.05.028 · Cited by 37
Reddel, C. J., Allen, J. D., Ehteda, A., Taylor, R., Chen, V. M. Y., Curnow, J. L., Kritharides, L., & Robertson, G. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13612 · Cited by 36
Yeh, J., Wei, Y.-F., Lin, C., & Hsu, W. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017657 · Cited by 36
Plasma cytokines and risk of coronary heart disease in the PROCARDIS study
Clarke, R., Valdés‐Márquez, E., Hill, M., Gordon, J., Farrall, M., Hamsten, A., Watkins, H. C., & Hopewell, J. C. (2018) · Open Heart · doi:10.1136/openhrt-2018-000807 · Cited by 36
Rizza, S., Copetti, M., Cardellini, M., Menghini, R., Pecchioli, C., Luzi, A., Cola, G. D., Porzio, O., Ippoliti, A., Romeo, F., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.029 · Cited by 36
Georgakis, M. K., Malik, R., Gill, D., Franceschini, N., Sudlow, C. L. M., & Dichgans, M. (2019) · medRxiv · doi:10.1101/19007682 · Cited by 36
Altered IL-6 signalling and risk of tuberculosis: a multi-ancestry mendelian randomisation study
Hamilton, F., Schurz, H., Yates, T., Gilchrist, J. J., Möller, M., Naranbhai, V., Ghazal, P., Timpson, N. J., Akhtar, S., Anwar, M., et al. (2024) · The Lancet Microbe · doi:10.1016/s2666-5247(24)00162-9 · Cited by 48
Rodrı́guez, S., Gaunt, T. R., Guo, Y., Zheng, J., Barnes, M. R., Tang, W., Danish, F.-I.-A., Johnson, A. D., Castillo, B. A., Li, Y. R., et al. (2015) · European Journal of Human Genetics · doi:10.1038/ejhg.2015.63 · Cited by 35
Soluble Interleukin-6 Receptor-Mediated Innate Immune Response to DNA and RNA Viruses
Wang, Q., Chen, X., Feng, J. J., Cao, Y., Song, Y., Wang, H., Zhu, C., Liu, S., & Zhu, Y. (2013) · Journal of Virology · doi:10.1128/jvi.01248-13 · Cited by 35
Happiness and Inflammatory Responses to Acute Stress in People With Type 2 Diabetes
Panagi, L., Poole, L., Hackett, R. A., & Steptoe, A. (2019) · Annals of Behavioral Medicine · doi:10.1093/abm/kay039 · Cited by 35
Interleukin-1 in Coronary Artery Disease
Oikonomou, E. K., Tsaplaris, P., Anastasiou, A., Xenou, M., Lampsas, S., Siasos, G., Pantelidis, P., Theofilis, P., Tsatsaragkou, A., Κατσαρού, Ο., et al. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666221017144734 · Cited by 35
Genomic Aging, Clonal Hematopoiesis, and Cardiovascular Disease
Natarajan, P. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318181 · Cited by 35
Atherosclerosis: Recent trials, new targets and future directions
Ladeiras‐Lopes, R., Agewall, S., Tawakol, A. A., Staels, B., Stein, E. A., Mentz, R. J., Leite-Moreira, A. F., Zannad, F. M., & Köenig, W. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.013 · Cited by 34
The Utility of Anti-Inflammatory Agents in Cardiovascular Disease
Kottoor, S. J., & Arora, R. R. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248418778548 · Cited by 34
Chen, Q., Li, L., Yi, J., Huang, K., Shen, R., Wu, R., & Yao, C. (2020) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1186 · Cited by 39
Hamer, M., Smith, L., & Stamatakis, E. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.02.009 · Cited by 34
O’Donoghue, M. L., Glaser, R., Aylward, P. E., Cavender, M. A., Crisp, A., Fox, K. A. A., Laws, I., López-Sendón, J. L., Steg, P. G., Théroux, P., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.02.012 · Cited by 33
van Wijk, D. F., Boekholdt, S. M., Arsenault, B. J., Ahmadi‐Abhari, S., Wareham, N. J., Stroes, E. S. G., & Khaw, K. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002823 · Cited by 33
Low levels of small HDL particles predict but do not influence risk of sepsis
Hamilton, F., Pedersen, K. M., Ghazal, P., Nordestgaard, B. G., & Smith, G. D. (2023) · Critical Care · doi:10.1186/s13054-023-04589-1 · Cited by 30
van Vugt, M., Finan, C., Chopade, S., Providencia, R. A., Bezzina, C. R., Asselbergs, F. W., van Setten, J., & Schmidt, A. F. (2024) · Genome Medicine · doi:10.1186/s13073-024-01395-4 · Cited by 37
Kuh, D. J., Cooper, R., Sattar, N. A., Welsh, P. I., Hardy, R., & Ben‐Shlomo, Y. (2019) · Circulation · doi:10.1161/circulationaha.118.037332 · Cited by 32
The application of ‘omics’ to pulmonary arterial hypertension
Harbaum, L., Rhodes, C. J., Otero‐Núñez, P., Wharton, J., & Wilkins, M. R. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15056 · Cited by 34
Croci, D. M., Wanderer, S., Strange, F., Grüter, B. E., Sivanrupan, S., Andereggen, L., Casoni, D. C., von Gunten, M., Widmer, H. R., Santo, S. D., et al. (2021) · Translational Stroke Research · doi:10.1007/s12975-020-00880-3 · Cited by 32
Ma, J., & Chen, X. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.631398 · Cited by 36
Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications
Montarello, N. J., Nguyen, M. T., Wong, D. T. L., Nicholls, S. J., & Psaltis, P. J. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07106-6 · Cited by 66
Emerging Risk Factors for Stroke
Hopewell, J. C., & Clarke, R. (2016) · Stroke · doi:10.1161/strokeaha.115.010646 · Cited by 31
Falco, A., Corso, L. D., Girardi, D., CARLO, A. D., & Comar, M. (2017) · Research in Nursing & Health · doi:10.1002/nur.21844 · Cited by 36
Inflammatory stress in islet β-cells: therapeutic implications for type 2 diabetes?
Lytrivi, M., Igoillo‐Esteve, M., & Cnop, M. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.08.002 · Cited by 29
Gremmels, H., Teraa, M., de Jager, S. C. A., Pasterkamp, G., de Borst, G. J., & Verhaar, M. C. (2019) · Scientific Reports · doi:10.1038/s41598-019-47217-1 · Cited by 31
Zhao, T. X., Newland, S. A., & Mallat, Z. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312287 · Cited by 32
Valdés‐Márquez, E., Clarke, R., Hill, M., Watkins, H. C., & Hopewell, J. C. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad020 · Cited by 32
IL6 genetic perturbation mimicking IL-6 inhibition is associated with lower cardiometabolic risk
Zhang, L., Omarov, M., Xu, L., deGoma, E. M., Natarajan, P., & Georgakis, M. K. (2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00700-7 · Cited by 32
A new regulatory variant in the interleukin-6 receptor gene associates with asthma risk
Revez, J. A., Bain, L., Chapman, B. M., Powell, J. E., Jansen, R., Duffy, D. L., Tung, J. Y., Collaborators, A., Matheson, M. C., Marks, G. B., et al. (2013) · Genes and Immunity · doi:10.1038/gene.2013.38 · Cited by 30
Anti-inflammatory agents in peripheral arterial disease
Antonopoulos, A. S., Papanikolaou, E., Vogiatzi, G., Oikonomou, E. K., & Tousoulis, D. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.11.001 · Cited by 31
Yokoe, I., Kobayashi, H., Kobayashi, Y., Giles, J. T., Yoneyama, K., Kitamura, N., & Takei, M. (2018) · Scandinavian Journal of Rheumatology · doi:10.1080/03009742.2017.1418424 · Cited by 30
Orrem, H. L., Nilsson, P. H., Pischke, S. E., Kleveland, O., Yndestad, A., Ekholt, K., Damås, J. K., Espevik, T., Bendz, B., Halvorsen, B. L., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02035 · Cited by 30
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 32
Ahmed, S., Jacob, B., Carsons, S. E., Leon, J. D., & Reiss, A. B. (2021) · Pharmaceuticals · doi:10.3390/ph15010011 · Cited by 30
Maierean, S. M., Webb, R. J., Banach, M., & Mazidi, M. (2022) · European Heart Journal Open · doi:10.1093/ehjopen/oeac039 · Cited by 32
Target Discovery for Drug Development Using Mendelian Randomization
Evans, D. S. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2573-6_1 · Cited by 30
Nolde, M., Alayash, Z., Reckelkamm, S. L., Kocher, T., Ehmke, B., Holtfreter, B., Baurecht, H., Georgakis, M. K., & Baumeister, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160148 · Cited by 30
Cederström, S., Lundman, P., Alfredsson, J., Hagström, E., Ravn‐Fischer, A., Söderberg, S., Yndigegn, T., Tornvall, P., & Jernberg, T. (2023) · Scientific Reports · doi:10.1038/s41598-023-39051-3 · Cited by 30
Novel Anti-Inflammatory Therapies in Coronary Artery Disease and Acute Coronary Syndromes
Dimitroglou, Y., Aggeli, C., Theofilis, P., Tsioufis, P., Oikonomou, E. K., Chasikidis, C., Tsioufis, K. P., & Tousoulis, D. (2023) · Life · doi:10.3390/life13081669 · Cited by 35
Gigante, B., Strawbridge, R. J., Velásquez, I. M., Golabkesh, Z., Silveira, A. M. V., Goel, A., Baldassarre, D., Veglia, F., Tremoli, E., Clarke, R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119980 · Cited by 30
Relationship between outdoor temperature and cardiovascular disease risk factors in older people
Sartini, C., Barry, S., Whincup, P. H., Wannamethee, S. G., Lowe, G. D. O., Jefferis, B. J. M. H., LENNON, L. T., Welsh, P. I., Ford, I., Sattar, N. A., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316682119 · Cited by 30
Wang, Y., Hu, Y., Sha, Y.-H., Gao, J.-J., Ma, X., Li, S., Zhao, J., Qiu, Y., Lu, J., Huang, C., et al. (2015) · Inflammation · doi:10.1007/s10753-015-0194-1 · Cited by 30
The landscape of the methodology in drug repurposing using human genomic data: a systematic review
Wang, L., Lü, Y., Li, D., Zhou, Y., Yu, L., Mesa‐Eguiagaray, I., Campbell, H. J., Li, X., & Τheodoratou, E. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbad527 · Cited by 32
Coveney, S. A., McCabe, J. J., Murphy, S., O'Donnell, M. J., & Kelly, P. J. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012825.pub2 · Cited by 30
Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations
Hu, Q., Hao, P., Liu, Q., Dong, M., Gong, Y., Zhang, C., & Zhang, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9537-4 · Cited by 30
Infections causing stroke or stroke-like syndromes
Pagliano, P., Spera, A. M., Ascione, T., & Esposito, S. (2020) · Infection · doi:10.1007/s15010-020-01415-6 · Cited by 28
Ulander, L., Tolppanen, H., Hartman, O., Rissanen, T. T., Paakkanen, R., Kuusisto, J. K., Anttonen, O. M., Nieminen, T. V. M., Yrjölä, J., Ryysy, R., et al. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.04.062 · Cited by 30
Asthma COPD overlap: Impact of associated comorbidities
Maselli, D. J., & Hanania, N. A. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.08.006 · Cited by 29
Human Genetics and Drug Development
Holmes, M. V. (2019) · New England Journal of Medicine · doi:10.1056/nejme1901565 · Cited by 28
Estimating inflammatory risk in atherosclerotic cardiovascular disease: plaque over plasma?
Annink, M. E., Kraaijenhof, J. M., Beverloo, C. Y. Y., Oostveen, R. F., Verberne, H. J., Stroes, E. S. G., & Nurmohamed, N. S. (2024) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeae314 · Cited by 29
IL-6 as a Mediator of Platelet Hyper-Responsiveness
Webb, C. E., Vautrinot, J., & Hers, I. (2025) · Cells · doi:10.3390/cells14110766 · Cited by 34
Grief Symptoms Promote Inflammation During Acute Stress Among Bereaved Spouses
Brown, R. L., LeRoy, A. S., Chen, M. A., Suchting, R., Jaremka, L. M., Liu, J., Heijnen, C. J., & Fagundes, C. P. (2022) · Psychological Science · doi:10.1177/09567976211059502 · Cited by 30
Mendelian Randomization and Type 2 Diabetes
Swerdlow, D. I. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6638-5 · Cited by 27
Self-citationTocilizumab-induced hypofibrinogenemia: A report of 7 cases
Martis, N., Chirio, D., Queyrel, V., Zenut, M.-C., Rocher, F., & Fuzibet, J. (2016) · Joint Bone Spine · doi:10.1016/j.jbspin.2016.04.008 · Cited by 27
Welsh, P. I., Tuckwell, K., McInnes, I. B., & Sattar, N. A. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.10.016 · Cited by 28
George, M. J., Kleveland, O., García-Hernández, J., Palmen, J., Lovering, R. C., Wiseth, R., Aukrust, P., Engmann, J., Damås, J. K., Hingorani, A. D., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015628 · Cited by 27
Roumeliotis, S. K., Veljkovic, A., Georgianos, P. I., Lazarević, G., Perišić, Z., Hadži-Djokić, J., Liakopoulos, V., & Kocic, G. M. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3090120 · Cited by 34
Nowakowska, M. K., Kim, T., Thompson, M. T., Bolton, K. L., Deswal, A., Lin, S. H., Scheet, P. A., Wehner, M. R., & Nead, K. T. (2022) · American Journal of Hematology · doi:10.1002/ajh.26465 · Cited by 28
Niu, Y., Bai, N., Ma, Y., Zhong, P.-Y., Shang, Y.-S., & Wang, Z.-L. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02525-9 · Cited by 26
Tackling inflammation in atherosclerosis: Are we there yet and what lies beyond?
Bhattacharya, P., Kanagasooriyan, R., & Subramanian, M. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102283 · Cited by 31
Metadata
- Authors
- Swerdlow, D. I.
- Affiliations
- University College London (GB)
- Corresponding author
- Daniel I. Swerdlow
- ORCID
- Daniel I. Swerdlow
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 379
- Issue
- 9822
- Pages
- 1214-1224
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC3316968
- OpenAlex
- W2143727405
- Cited by
- 1,146
- References
- 100
- Citations by year
- 2026: 78 · 2025: 86 · 2024: 94 · 2023: 89 · 2022: 84 · 2021: 110 · 2020: 89 · 2019: 80 · 2018: 74 · 2017: 77 · 2016: 67 · 2015: 56 · 2014: 63 · 2013: 65 · 2012: 32
- FWCI
- 8.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Bristol Research (University of Bristol) (publishedVersion, cc-by)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Lithuanian University of Health Sciences (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- MRC population health scientist fellowship (G0802432)
- National Institutes of Health (NIH), the MRC, and the British Heart Foundation (BHF (RG/10/12/28456)
- BHF (Schillingford) clinical training fellowship (FS/07/011)
- US National Heart, Lung, and Blood Institute (HHSN268200900009C)
- National Human Genome Research Institute (U01HG005152)
- Cancer Research UK (C1298/A8362, C150/A5660)
- IKEM (Czech Republic) (00023001)
- National Institute for Healthy Ageing (05060810)
- NIH/NHLBI (5215810-55000000041)
- BHF (RG 08/008 and PG/07/133/24260, RG/04/003)
- Netherlands Organisation for Health Research and Development (90700342)
- BHF senior fellowship (FS 05/125)
- British Heart Foundation (RG/10/12/28456)
- contract no. (HHSN268200625226C)
- NHLBI in collaboration with MESA investigators (N01 HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, and RR-024156)
- Wellcome Trust (064947/Z/01/Z and 081081/Z/06/Z)
- National Institute on Aging (1R01 AG23522-01)
- Intramural Research Program of the National Institute on Aging, NIH, Department of Health and Human Services (Z01 AG000954-06, ISGS (R01 NS42733), (R01 NS39987), Z01 AG000015-50)
- European Commission (QLG1-CT-2002-00896)
- Dutch Kidney Foundation (Grant E033)
- GENECURE (FP-6 LSHM CT 2006 037697)
- NIH (grant LM010098)
- The Netherlands Organisation for Health Research and Development (grant 916.761.70)
- European Union's Seventh Framework Programme (FP7/2007-2013)
- NHLBI (RFP-NHLBI-WH-11-10, HL36310)
- Veni grant Organization for Scientific Research (NWO) (2001.064)
- NIH; National Institute on Aging (AG13196)
- MRC (grant NHLBI 33014)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- IL-6 receptor, tocilizumab, coronary artery disease, primary prevention, C-reactive protein, fibrinogen, rheumatoid arthritis, genetic variants, monoclonal antibodies
- MeSH terms
- Coronary Disease, Gene Frequency, Genotype, Humans, Phenotype, Genetic Variation, Signal Transduction, Randomized Controlled Trials as Topic, Treatment Outcome, Inflammation Mediators, Receptors, Interleukin-6, Polymorphism, Single Nucleotide, Genetic Association Studies, Mendelian Randomization Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
